Background: In 2015 in Austria, 1,671 people died from pancreatic cancer, 8% of all cancer-related deaths, while only being responsible for 4% of malignant neoplasms. Worldwide this number was 338.000. Since it is often discovered in later stages and due to its properties of having already spread in most cases, five-year survival still is only around 9% (2008-2012), although the one-year survival increased to 36% (2013-2015) from 23% (1998-2002) due to better treatment options. A possible technique to predict overall survival could be 18F-FDG-PET/CT. In this study we tested the changes in SUVmax (standardized uptake value), tumor density in HU (Hounsfield Units) and the size of the primary lesion as possible prognostic markers of overall survival in patients with non-surgical treatment. Materials and Methods: This is a single-arm, retrospective, single-institution analysis, with 82 patients who underwent at least two 18F-FDG-PET/CT-scans since 2010 during the treatment of their pancreatic cancer with radiotherapy, chemotherapy, or combined radiochemotherapy. For our markers to be significant, patients who underwent surgery between those scans had to be omitted. Finally, 29 patients met our criteria. Two experts, blinded to all clinical data, concentrated on the evaluation of the 18F-FDG-PET/CT scans. Dichotomization for statistical evaluation was achieved by splitting the collective using the median observed value for SUVmax, HU and size. Two-year survival after a 4-month landmark from the first scan (to account for a possible immortal time bias) was calculated by using the Kaplan-Meier estimator. Log-Rank test was used to calculate the significance of the prognostic value. Results: None of the three markers showed statistical significance regarding the prognostic value concerning overall survival in our collective. Mean survival was 471 days in the group with a higher decrease in SUVmax vs. 342 days in the group with lesser decrease or increase (P=0.073), 342 days in the group with a higher decrease in size vs. 471 days in the group with lesser or no decrease in size (P=0.151), and 451 days in the group having a higher decrease in tumor density vs. 362 days in the group showing no decrease or an increase in tumor density (P=0.695). Conclusion: Of all observed markers, although none had a significant result, only SUV showed the possibility of being useful for depicting the survival in patients with pancreatic cancer, as some other studies with similar sample sizes have shown. Larger, prospective multi-center studies are therefore needed to confirm, if there indeed is a positive correlation between a decrease in FDG-uptake and overall survival.